The landscape of d16HER2 splice variant expression across HER2-positive cancers
Author:
Funder
Associazione Italiana per la Ricerca sul Cancro
PRIN2015
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-019-40310-5.pdf
Reference40 articles.
1. Tagliabue, E., Balsari, A., Campiglio, M. & Pupa, S. M. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 10, 711–724 (2010).
2. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
3. Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17, 738–746 (2016).
4. Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 8, 49–58 (2018).
5. Siravegna, G. et al. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell 34, 148–162 (2018).
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24
2. Resistance of HER2-expressing breast cancer patients treated with trastuzumab: Underlying mechanisms of resistance and reversals;Overcoming Cancers Resistant to HER-2 Antibodies;2024
3. Growth Factor Receptor Implications in Breast Cancer: Prospects for Their Molecular Transactivation in the Future and Obstacles for Target Therapy;Interdisciplinary Cancer Research;2024
4. HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer;Cancer Immunology Research;2023-06-13
5. A review of HER2 overexpression and somatic mutations in cancers;Critical Reviews in Oncology/Hematology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3